.webp)
67/100BRoyalty Pharma stock forecast 2026–2029What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Royalty Pharma is 66.50, 1.2% below the current price of 67.29. Their targets range from 66.00 to 67.00.
Of the 5 firms that rated Royalty Pharma in the past 12 months, 5 rate it buy or strong buy, 0 hold and 0 sell or strong sell (each firm at its latest rating): a Strong buy consensus.
Analysts' 1-year price targets range from 66.00 to 67.00, with an average of 66.50.
| Buy | 5 | |
| Hold | 0 | |
| Sell | 0 |
12-month price target
| Highest target | 67.00 |
| Average target | 66.50 |
| Lowest target | 66.00 |
| Current price | 67.29 |
Royalty Pharma price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their Royalty Pharma price target and rating?
How analysts rate Royalty Pharma, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
5 of 5 firms rate it buy now, against 3 of 3 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Royalty Pharma analyst upgrades, downgrades and price targets
The latest rating change came on 30 January 2026, when UBS upgraded Royalty Pharma from Neutral to Buy. Its price target is 49.00. The most recent new target came from Morgan Stanley on 7 October 2026: 67.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 7 Oct 2026 | Morgan Stanley | Reiterated · Overweight | 65.00 → 67.00 | +3.1% | 56.93 |
| 6 Aug 2026 | Goldman Sachs | — | 42.00 → 66.00 | +57.1% | 57.02 |
| 6 Aug 2026 | Morgan Stanley | — | 63.00 → 65.00 | +3.2% | 57.75 |
| 21 Apr 2026 | UBS Ashwani Verma | Reiterated · Buy | 49.00 → 57.00 | +16.3% | 49.30 |
| 10 Apr 2026 | Morgan Stanley Terence Flynn | Reiterated · Overweight | 61.00 → 63.00 | +3.3% | 47.98 |
| 27 Feb 2026 | Seaport Global | — | 50.00 | — | 46.21 |
| 12 Feb 2026 | Morgan Stanley Terence Flynn | — | 54.00 → 61.00 | +13.0% | 44.71 |
| 30 Jan 2026 | UBS Ashwani Verma | Upgraded · Neutral → Buy | 49.00 | — | 40.86 |
| 11 Dec 2025 | Leerink Partners | — | 45.00 | — | 38.22 |
Royalty Pharma EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Royalty Pharma's EPS to grow 81.2% a year until 2027. Over the last 5 years it grew 7.1% a year, and over the last 3 years 162.1%.
Analysts expect Royalty Pharma's revenue to grow 20.9% a year until 2028, faster than over the last 5 years (2.3% a year) and the last 3 years (2.1%).
Revenue
EPS
Does Royalty Pharma beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 9.2% off the result, either way, and their revenue estimate 11.4%, over the last 12 quarters.
- EPS beats
- 19 / 26
- Revenue beats
- 8 / 26
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +9.0%
- Since
- August 2020
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 4 Nov 2026 | 1.18 | 1.21 | +2.5% | 884.84M | 890.00M | +0.6% |
| Q2 FY2026 | 5 Aug 2026 | 1.27 | 1.32 | +3.9% | 758.93M | 773.00M | +1.9% |
| Q1 FY2026 | 6 May 2026 | 1.21 | 1.30 | +7.4% | 881.69M | 925.00M | +4.9% |
| Q4 FY2025 | 11 Feb 2026 | 1.29 | 1.46 | +13.2% | 806.96M | 874.00M | +8.3% |
| Q3 FY2025 | 5 Nov 2025 | 0.99 | 1.17 | +17.7% | 717.38M | 609.29M | -15.1% |
| Q2 FY2025 | 6 Aug 2025 | 1.03 | 1.14 | +10.7% | 672.99M | 578.67M | -14.0% |
| Q1 FY2025 | 8 May 2025 | 0.95 | 1.06 | +11.2% | 705.34M | 568.25M | -19.4% |
| Q4 FY2024 | 11 Feb 2025 | 0.99 | 1.15 | +16.2% | 687.10M | 594.00M | -13.5% |
| Q3 FY2024 | 6 Nov 2024 | 0.93 | 1.04 | +12.1% | 696.92M | 564.69M | -19.0% |
| Q2 FY2024 | 8 Aug 2024 | 0.97 | 0.96 | -0.5% | 627.42M | 537.27M | -14.4% |
| Q1 FY2024 | 9 May 2024 | 0.99 | 0.98 | -0.7% | 665.57M | 567.98M | -14.7% |
| Q4 FY2023 | 15 Feb 2024 | 1.01 | 1.15 | +13.9% | 673.65M | 596.00M | -11.5% |
Royalty Pharma stock price 2026–2029: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Royalty Pharma's earnings keep growing at the 10.6% a year analysts expect to FY2027, it would earn about 7.23 a share in FY2029. At the P/E it has traded at over the last five years (8.2 to 39.8) that is 59.58 to 287.94 a share, or 151.41 at its average P/E of 20.9. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 5.39 | 44.42 | 112.88 | 214.66 |
| FY2027 | 5.91 | 48.69 | 123.72 | 235.29 |
| FY2028 (extrapolated) | 6.54 | 53.86 | 136.87 | 260.29 |
| FY2029 (extrapolated) | 7.23 | 59.58 | 151.41 | 287.94 |
Each year's EPS is the analysts' consensus to FY2027; the years after grow 10.6% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (8.2, 20.9, 39.8).
Is Royalty Pharma stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Royalty Pharma's P/E of 39.8 is above the middle of its 5-year range (8.2 to 3,021.0, median 20.5). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Buyers pay less for each point of growth than usual: a PEG of 0.5 on expected growth against 2.9 on its median P/E and past five years' growth. At the median P/E of its peers (37.3 × EPS of 1.69), Royalty Pharma's fair value is 63.11; the price, 67.29, is 6.6% above it. Its forward P/E, on the consensus for FY2026, is 12.5.
Fair value on the peers is the median P/E of the US companies of its industry closest in size times its earnings per share of the last twelve months; the ends of the bar are the same earnings at the lowest and highest peer P/E (28.3 and 55.4). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 39.81
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 20.49
- Five-year P/E range
- 8.2 – 3,021.0
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 12.48
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.75
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- -1.2%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.